**Syndax Pharmaceuticals** is a biotechnology company founded in **2005** and is headquartered in the **United States** at 35 Gatehouse Dr., Building D, Floor 3, Waltham, MA 02451. Specializing in the **Biotechnology, Health Care, and Pharmaceutical** industries, the company recently received a significant **$230.00M** Post-IPO Equity investment on **14 December 2023**. This substantial investment demonstrates the confidence of the investment community in Syndax Pharmaceuticals and its potential for growth and impact in the biotechnology and healthcare sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $230.00M | - | 14 Dec 2023 | |
| Post-IPO Equity | $150.00M | - | 06 Dec 2022 | |
| Post-IPO Equity | $75.30M | - | 15 Dec 2021 | |
| Post-IPO Debt | $30.00M | 5 |
|
31 Jan 2020 |
| Post-IPO Equity | $50.00M | - | 01 Aug 2019 |
No recent news or press coverage available for Syndax Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
